Dendreon Corp fka DNDNQ

[DewDiligence]

The FDA non-approval has presumably softened patient interest in enrolling to some degree. Nonetheless, guidance for completed enrollment by year-end is lame and, given DNDN’s history of failing to meet enrollment targets, this target probably won’t be met.

There is evidently more enthusiasm for Provenge from the message-board community than there is from the pool of individuals who might benefit from taking the drug.